Tango Therapeutics, Inc. is recruiting patients for a PHASE1/PHASE2 clinical trial testing pembrolizumab (Keytruda) for mesothelioma.
The trial, designated NCT05732831, aims to enroll up to 225 participants at 26 sites, including locations in California, Colorado, Florida.
About the Study
This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific MTAP-deleted tumor types. The study drug, TNG462, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 225 participants.
Treatment Approach
This trial uses a PD-1 checkpoint inhibitor that helps the immune system recognize and attack cancer cells.
Key trial details:
- Phase: PHASE1/PHASE2
- Sponsor: Tango Therapeutics, Inc.
- Enrollment target: 225
- Status: RECRUITING
Why This Trial Matters
Study Locations
The trial is recruiting at:
- Stanford University, California
- Grand Valley Oncology, Colorado
- Florida Cancer Specialists & Research Institute, Florida
- Sylvester Comprehensive Cancer Center, Florida
- University Chicago Medicine, Illinois
How to Enroll
Patients interested in this trial should:
- Discuss eligibility with their oncologist
- Review the full eligibility criteria on ClinicalTrials.gov
- Contact the study coordinator for screening